Ceruloplasmin is a human gene whose product fITM2 (Fat Storage-Inducing Transmembrane Protein 2) is an endoplasmic reticulum membrane protein involved in lipid droplet biogenesis and triglyceride storage. While initially characterized for its role in adipocyte lipid metabolism, FITM2 has emerged as a critical regulator of neuronal lipid homeostasis and mitochondrial function [1]. Variants in Ceruloplasmin have been implicated in Neurodegeneration with Brain Iron Accumulation (NBIA), Hereditary Spastic Paraplegia-like Phenotype, Developmental Disorders. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
Function
FITM2 (Fat Storage-Inducing Transmembrane Protein 2) is an endoplasmic reticulum membrane protein involved in lipid droplet biogenesis and triglyceride storage. While initially characterized for its role in adipocyte lipid metabolism, FITM2 has emerged as a critical regulator of neuronal lipid homeostasis and mitochondrial function [1].
In [neurons](/entities/neurons), FITM2 functions include:
Regulating lipid droplet formation for neutral lipid storage
Protecting against lipotoxicity during metabolic stress
Supporting myelin lipid composition in oligodendrocytes [2]
FITM2 acts synergistically with FITM1 to partition triglycerides into lipid droplets, preventing accumulation of toxic lipid intermediates that can damage cellular membranes and organelles. In the brain, this function is particularly important for neurons with high metabolic demands and for maintaining the lipid-rich myelin sheath [3].
Disease Associations
Neurodegeneration with Brain Iron Accumulation (NBIA)
Biallelic FITM2 mutations cause a novel form of neurodegeneration with brain iron accumulation (NBIA). Clinical features include:
Progressive dystonia and parkinsonism
Intellectual disability and developmental delay
Optic atrophy
Brain iron accumulation visible on MRI (globus pallidus, substantia nigra)
Cerebellar atrophy [4]
The pathogenic mechanism involves disrupted lipid homeostasis leading to mitochondrial dysfunction, oxidative stress, and iron dysregulation in susceptible brain regions.
Hereditary Spastic Paraplegia-like Phenotype
FITM2 variants have been associated with:
Progressive lower limb spasticity
Peripheral neuropathy
Cognitive impairment
Developmental Disorders
Early-onset presentations include:
Global developmental delay
Microcephaly in some cases
Movement disorders
Expression
FITM2 expression patterns relevant to neurodegeneration:
Brain: High expression in [basal ganglia](/brain-regions/basal-ganglia), substantia nigra, cerebellum
Spinal cord: Motor neurons
Peripheral nerve: Schwann cells
Adipose tissue: Brown and white adipocytes
FITM2 is co-expressed with lipid metabolism genes and shows elevated expression during periods of active myelination [5].
Therapeutic Implications
Iron Chelation
For FITM2-related NBIA:
Deferiprone or deferroxamine may reduce brain iron accumulation
See [Deferiprone for neurodegeneration](/therapeutics/deferiprone-neurodegeneration)
Mitochondrial Support
Coenzyme Q10 supplementation
[NAD+ precursors](/therapeutics/nad-precursors-neurodegeneration) to support mitochondrial function
Antioxidant therapy
Symptomatic Management
Baclofen or botulinum toxin for dystonia
Physical therapy for motor symptoms
Occupational therapy for daily living skills
Monitoring for optic nerve involvement
Experimental Approaches
Gene therapy targeting lipid metabolism pathways
Small molecule enhancers of lipid droplet biogenesis
Substrate reduction therapy to limit toxic lipid accumulation
Related Genes and Pathways
FITM1: Fat storage-inducing transmembrane protein 1